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Abstract
Corneal keratoplasty (penetrating or lamellar) using cadaveric human tissue, is nowadays
the main treatment for corneal endotelial dysfunctions. However, there is a worldwide short-
age of donor corneas available for transplantation and about 53% of the world’s population
have no access to corneal transplantation. Generating a complete cornea by tissue engi-
neering is still a tough goal, but an endothelial lamellar graft might be an easier task. In this
study, we developed a tissue engineered corneal endothelium by culturing human corneal
endothelial cells on a human purified type I collagen membrane. Human corneal endothelial
cells were cultured from corneal rims after corneal penetrating keratoplasty and type I colla-
gen was isolated from remnant cancellous bone chips. Isolated type I collagen was ana-
lyzed by western blot, liquid chromatography -mass spectrometry and quantified using the
exponentially modified protein abundance index. Later on, collagen solution was casted
at room temperature obtaining an optically transparent and mechanically manageable
membrane that supports the growth of human and rabbit corneal endothelial cells which
expressed characteristic markers of corneal endothelium: zonula ocluddens-1 and Na+/K+
ATPase. To evaluate the therapeutic efficiency of our artificial endothelial grafts, human
purified type I collagen membranes cultured with rabbit corneal endothelial cells were trans-
planted in New Zealand white rabbits that were kept under a minimal immunosuppression
regimen. Transplanted corneas maintained transparency for as long as 6 weeks without
obvious edema or immune rejection and maintaining the same endothelial markers that in a
healthy cornea. In conclusion, it is possible to develop an artificial human corneal endothelial
graft using remnant tissues that are not employed in transplant procedures. This artificial
endothelial graft can restore the integrality of corneal endothelium in an experimental model
of endothelial dysfunction. This strategy could supply extra endothelial tissue and compen-
sate the deficit of cadaveric grafts for corneal endothelial transplantation.
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Introduction
Corneal transplantation is the main treatment for patients suffering corneal endothelial dys-
functions. Nevertheless, an important problem in several countries of the world is the shortage
of donors, and about 53% of the world’s population have no access to corneal transplantation
[1]. New therapeutic approaches have been appeared in recent years. Medical treatment with
ROCK kinase inhibitor [2] and cell therapies associated with ROCK kinase inhibitor [3] are
currently being evaluated. Despite the promise of these new therapeutics, keratoplasty from
corneal cadaveric donors remains the gold standard for endothelial diseases.
Penetrating keratoplasty (PK) has traditionally been the treatment of choice for eyes with a
damaged endothelial layer such as in Fuchs’ endothelial dystrophy or in pseudophakic bullous
keratopathy. However, there are several drawbacks with regard to PK such as graft rejection,
suture-related problems, infection and astigmatism. New surgical options, such as Descemet’s
membrane endothelial keratoplasty (DMEK) or Descemet’s striping automated endothelial ker-
atoplasty (DSAEK), have become increasingly popular since they tend to optimize corneal
resources by replacing only the damaged part of the cornea [4–7]. These new techniques require
even better endothelial quality in order to perform the corneal graft (cell density, hexagonality
ratio, etc), so only 30–35% of the corneas are suitable for lamellar endothelial keratoplasty [8].
A DMEK graft consists of a monolayer of corneal endothelial cells (CECs) on its Descemet
´s membrane. Reproducing this structure by tissue engineering techniques requires a scaffold
that mimics the Descemet´s membrane and a source of cells capable of restoring the endothe-
lial function, reflecting two critical determinants for a successful tissue engineered product:
the in vitro culture of human CECs and the development of a scaffold that provides the appro-
priate environment for cells.
Human CECs are considered as non-proliferative in vivo, since they are arrested in G1
phase [9,10]. Therefore the number of human CECs decreases with age [11] and in several dis-
eases such as endothelial dystrophy, glaucoma, or cataract surgery [12,13]. On the other hand,
several studies have shown that human CECs can be induced to divide to a limited extent in
vitro [14] so that expansion of cultured human CECs could potentially allow many patients to
be treated using one donor, decreasing some of the current donor shortage problems.
Different carriers have been used as scaffold for endothelial tissue engineering such as
denuded Descemet´s membrane [15,16], amniotic membrane [17], gelatin membrane [18–
21], anterior lens capsule [22], silk fibroin membrane [23], and different synthetic polymers
[24]. In recent years, several groups have been using natural [25–27] or recombinant [28] col-
lagen scaffolds for the culture of human CECs, being porcine [29] or bovine [30,31] type I col-
lagen the most widely used.
Type I collagen is the most abundant protein constituting approximately 25 to 30% of all
proteins of human body [32]. It is also an important component of all connective tissues of the
body: muscle, teeth, bone and skin [33]. A natural source of type I collagen is cancellous bone
[34]. Human cancellous bone is the second most processed, distributed and grafted tissue
worldwide, coming right after blood transfusion [35]. The remnant cancellous bone generated
during the preparation of bone chips could be a new safe source of human type I collagen.
Culturing human CECs is not an easy task since most of the corneas are used for tissue
transplant and those that are discarded have a limited cell density. During corneal transplant,
peripheral Descemet’s membrane is usually discarded and only its central button is used for
graft applications. The unused endothelial tissue may be used in regenerative medicine for the
development of a tissue-engineered endothelium since they come from an optimal cell source.
The aim of this study was the development of a new approach for endothelial tissue engi-
neering using products normally processed in tissue banks: remnants of human cancellous
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bone chips and Descemet’s peripheral rings of corneas previously used for PK. With this
approach we were able to produce an artificial corneal endothelial graft, using human purified
type I collagen membranes (HPCM) with confluent human and rabbit CECs expressing char-
acteristic corneal endothelial markers. Finally, this artificial lamellar endothelium was grafted
in an experimental rabbit model to restore an endothelial dysfunction, leading to complete
recovery of corneal transparency and thickness at 6 weeks.
Materials and Methods
Donors
Human tissue was handled according to the Declaration of Helsinki. Corneal tissue and fresh
human cancellous bone were obtained, stored and processed at the Asturias regional tissue
bank (Centro Comunitario de Sangre y Tejidos, Oviedo, Asturias, Spain) according to Spanish
laws.
Collagen type I isolation and quantification
Collagen isolation was performed as previously described [36]. Briefly, 10 cancellous bone
chips samples (between 5 and 15cm3 of bone) were received from the local tissue bank and
stored at -80˚C until use.
Cancellous bone chips were milled and demineralized using an adaptation of a previously
reported method [37]. In brief, the granules were demineralized under agitation (300rpm) in
0.5N HCl (25ml/g of bone) at room temperature for 24h. After demineralization the resultant
material was rinsed with distilled water. The lipids in the demineralized powder were then
rinsed out under agitation with a 1:1 mixture of chloroform and methanol for 1h at room tem-
perature and then repeatedly rinsed, first in methanol and then, in distilled water. The material
was then freeze-dried in a Lyoquest -85˚ Eco (Telstar, Tokyo, Japan) and stored at -80˚C until
required.
A previously reported pepsin digestion and solubilization technique [38] was employed for
the isolation of type I collagen. Lyophilized samples were digested in a 100ml/g 0.01N HCl
solution containing 1mg/ml pepsin (Sigma-Aldrich, MO, USA). The suspension was agitated
at room temperature for 96h, centrifuged at 10,000xg for 30 minutes, the precipitate discarded,
and then aliquoted and stored at -80˚C until required.
The collagen concentration was determined using a hydroxyproline assay kit (Sigma-
Aldrich, MO, USA). The hydroxyproline content of pepsin digested collagen was determined
by the oxidized hydroxyproline with 4-(Dimethylamino)benzaldehyde (DMAB) reaction,
which results in a colorimetric (560nm) product, proportional to the hydroxyproline present.
The total collagen content (mg/ml) of the digests was determined using the relationship that
hydroxyproline forms 14% of total collagen [39].
Gel electrophoresis and western-blot
Electrophoresis was carried out as described by Laemmli [40], using 8% separating gels, which
were 1.5mm thick. Samples containing 20.7μg purified collagen and human commercial colla-
gen (Millipore, MA, USA) as control were boiled at 100˚C for 5 minutes prior to gel loading.
Gels were electrophoresed at 100V (constant voltage) followed by transfer onto a polyvinyli-
dene fluoridemembrane (PVDF, 120V, 40 minutes). After transfer, PDVF membranes were
immunoblotted with anti-type I collagen antibody (1:200), and 10% normal goat serum
(Abcam, Cambridge, UK) as a blocking agent, overnight at 4˚C. Proteins were visualized using
a Fusion FX7 chemiluminiscence detection system (VilberLourmat, Torcy, France).
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Collagen purity assessment
For purity assessment, six random samples were analyzed by liquid chromatography–mass
spectrometry (LC/MS).
Samples were incubated at room temperature with ammonium bicarbonate (50mM, final
volume of 50μl) in 8M urea. After 30 minutes 4μl of ditiothreitol (DTT, 200mM in 50mM
ammonium bicarbonate) was added and incubated at room temperature for 60 minutes, fol-
lowed by incubation in iodoacetamide (IA, 50mM in 50mM ammonium bicarbonate, 5μl) for
another 60 minutes in the dark. Excess of IA was quenched by adding 20μl DTT (200mM in
50mM ammonium bicarbonate). Finally, samples were diluted up to a concentration of 1.5M
urea, and incubated with trypsin (12.5μg/ml in 50mM ammonium bicarbonate) overnight at
37˚C. After digestion, samples were dried out in a RVC2 25 speedvac concentrator (Christ,
Osterode am Harz, Germany).
LC was performed using an NanoAcquity nano-HPLC (Waters, MA, USA), equipped with
a Waters BEH C18 nano-column (200mm x 75μm ID, 1.8μm), a chromatographic ramp of 30
minutes (5 to 60% ACN) was used with a flow rate of 300nl/minute. Mobile phase A was water
containing 0.1% v/v formic acid, while mobile phase B was CAN containing 0.1% v/v formic
acid. A lock mass compound [Glu1]-Fibrinopeptide B (100fmol/μl) was delivered by an auxil-
iary pump of the LC system at 500nl/minute to the reference sprayer of the NanoLockSpray
(Waters, MA, USA) source of the mass spectrometer. 0.5μg of each sample were loaded for
each run.
MS was performed using a Synapt G2Si ESI Q-Mobility-TOF spectrometer (Waters, MA,
USA) equipped with an ion mobility chamber (T-Wave-IMS) for high definition data acquisi-
tion analyses. All analyses were performed in positive mode ESI. Data were post-acquisition
lock mass corrected using the double charged monoisotopic ion of [Glu1]-Fibrinopeptide B.
Accurate mass LC-MS data were collected in HDDA mode that enhances signal intensities
using the ion mobility separation step.
Database searching was performed using MASCOT 2.2.07 (Matrixscience, London, UK)
against a UNIPROT—Swissprot database filled only with entries corresponding to Homo sapi-
ens (without isoforms). For protein identification the following parameters were adopted: car-
bamidomethylation of cysteines as fixed modification and oxidation of methionines, and
hydroxylation as variable modifications, 10ppm of peptide mass tolerance, 0.5Da fragment
mass tolerance and up to 3 missed cleavage points, Peptide charges of +2 and +3.
Content of purified proteins was quantified using the Exponentially Modified Protein
Abundance Index (emPAI) as previously described [41]. The protein contents in molar frac-
tion percentages (mol%) were calculated according to the following equation:
mol% ¼
emPAI
SðemPAIÞ
 
100
The identified proteins were categorized into three groups: type I collagen, other collage-
nous proteins and non-collagenous proteins.
Preparation of the collagen membranes
An amount of 3mg/cm2 isolated type I collagen was casted into a silicone mold and air-dried
at room temperature. To improve their resistance, HPCM were crosslinked according to mod-
ified existing protocols [42]. Briefly, ultraviolet light (UV) irradiation was conducted by plac-
ing HPCM in a glass dish into a BLX-E254 254nm UV irradiation lamp (VilberLourmat,
Torcy, France) exposed to a UV intensity of 3.19mW/cm2/s during 100 minutes.
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Optical analysis and mechanical testing
The entire tests were carried out at 20±0.1˚C and before starting any measurements, the sam-
ples rested for at least 5 minutes, allowing the stresses induced during samples load to relax.
This study was performed employing pre-wet (1X PBS for 24h at room temperature) 10mm
diameter HPCM. All tests were carried out at least in duplicate.
Light transmission measurements were made using a narrow spectral region between 400
and 700nm using a SPELEC Spectroelectrochemical Instrument (Dropsens, Asturias, Spain)
equipped with a Deuterium 215-400nm and Tungsten Halogen 360–2,500nm light source and
a linear silicon CCD array with a detection range 200-900nm detector. A human cornea (74
years old) was employed as a control.
The crosslinked and non-crosslinked HPCM samples were mechanically tested with a TA.
TXplus (Stable Micro Systems) texturometer with a 5mm diameter SMS P/5 S spherical probe
in order to obtain the burst strength (g) and the distance at burst (mm) of the HPCM.
Statistical analyses were performed using IBM SPSS software. Significant differences among
defined groups were tested using the t test. A difference level of p<0.05 was considered as sta-
tistically significant.
Isolation and culture of corneal endothelial cells on HPCM
Corneal endothelial cells were cultured in Optimem I (Life Technologies, CA, USA) supple-
mented with 8%v/v FBS, 20μg/ml ascorbic acid 2-phosphate, 0.08% chondroitin sulfate,
200mg/l calcium chloride, 10U/ml penicillin and 10 μg/ml streptomycin (Sigma-Aldrich, MO,
USA) and 5ng/ml epidermal growth factor (Austral Biologicals, CA, USA).
Human CECs were obtained from 26 peripheral endothelial rings from corneas previously
used for PK which were maintained in Eusol-C storage medium (Alchimia, Ponte S. Nicolò,
Italy) at 4˚C for less than 10 days before use. The mean age of corneal donors was 63±2.17
years old and the endothelial cell density, determined prior to the surgery using a Cellcheck
specular endothelial microscope (Konan Medical, USA), was 2,653±82.51 cells/mm2. Desce-
met´s membrane along with endothelial cells were carefully peeled off under a dissecting
stereomicroscope following the Schwalbe line, and the peripheral endothelial ring was main-
tained overnight at 37˚C in a culture plate (2cm2), previously treated with FNC coating Mix1
(Athena Enviromental Sciences, MD, USA), with 1ml culture medium. The following day, the
excess medium was removed to a volume of 150μl and then, the peripheral endothelial ring
was placed as an explant in the culture plate.
Rabbit corneal endothelial cells (rabbit CECs) were isolated from healthy New Zealand
white male rabbits (2 months and 2.0–2.5kg in body weight) obtained from the Animal
Housing of the University of Oviedo (Oviedo, Asturias, Spain). All animals were treated in
accordance with the Association for Research in Vision and Ophthalmology (ARVO) state-
ment for use of animals in ophthalmic and vision researches. The protocols were approved
(PROAE 24/2016) by the Committee on the Ethics of Animal Experiments of the University
of Oviedo and the Animal Production and Health Service of Asturias. Rabbits were kept
under a 12/12 day/night light cycle with food and water ad libitum and were monitored on
a daily basis.
Descemet´s membrane along with endothelial cells were carefully peeled and digested with
trypsin/EDTA 0.25% (Sigma-Aldrich, MO, USA) for 30 minutes at 37˚C. After that, the tryp-
sin was neutralized with culture medium. The loosened cells were centrifuged using an Eppen-
dorf 5702R centrifuge (Eppendorf, Hamburg, Germany) at 0.4rcf for 10 minutes and the
supernatant was removed. Fresh medium was added and the cells were seeded on a culture
plate previously treated with FNC coating Mix1.
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When human or rabbit cultures were confluent, cells were digested with accutase (Sigma-
Aldrich, MO, USA). The loosened cells were centrifuged using an Eppendorf 5702R centrifuge
at 0.4rcf for 10 minutes and the supernatant was removed. Fresh medium was added and the
cells were seeded onto a HPCM using a device (11mm diameter) [43] that facilitates handling,
cell culture and transport of the membranes.
All cells were cultivated under the same conditions (humidified atmosphere at 37˚C, 5%
CO2, medium changed 3 times per week).
Examination of cell cultures
Cellular growth was assessed using a Leica DMIL LED phase contrast microscope (Leica, Wet-
zlar, Germany); photos were taken with an attached EC3 camera (Leica, Wetzlar, Germany).
Confluent cultured HPCM were fixed using ice-cold methanol for 10 minutes for their
analysis by phase contrast microscopy, scanning electron microscopy (SEM) and immunocy-
tochemistry. Methanol fixed cultured HPCM were divided in two parts, one half was rinsed
with PBS solution twice for 10 minutes and permeabilized in a PBS solution containing 0.3%
Triton-X100 for another 10 minutes. Next, the samples were incubated with primary antibody
containing 10% normal goat serum (Abcam, Cambridge, UK) at 4˚C overnight. Mouse Na+/
K+ ATPase (Millipore, MA, USA) (1:100), rabbit zonula ocluddens-1 (ZO-1) (Life Technolo-
gies, CA, USA) (1:100) and rabbit type IV collagen (Abcam, Cambridge, UK) (1:100) single
immunostains were performed in order to confirm their phenotype. Subsequently, the samples
were incubated with corresponding secondary antibody (Life Technologies, CA, USA) (1:500)
for 2h at room temperature. Between incubations samples were washed 3 times with PBS for
10 minutes. Immunolabeled cells were stained with DAPI to allow nuclei visualization.
The other half was cryoprotected in 30% sucrose at 4˚C for 24h and frozen embedded in Tis-
sue-Tek1 O.C.T.TM Compound (Sakura Finitek Europe B.V., Zoeterwoude, The Netherlands).
Next, 10μm sections were cut with a cryostat (Leica, Nussloch, Germany) and placed on commer-
cially treated slides (Fisher-Scientific, PA, USA). Immunostaining was performed as described in
the previous section using antibodies against ZO-1, Na+/K+ ATPase and type IV collagen.
All the samples were critically examined in a Leica DM6000B fluorescence microscope
(Leica, Wetzlar, Germany).
Surface morphology of cultured and non-cultured HPCM was examined by SEM. HPCM
fixed in ice-cold methanol were rinsed in PBS, followed by dehydration through a graded series of
acetone (30%, 50%, 70%, 90% and 100%) for 10 minutes respectively and dried by the critical-
point method. Afterwards, they were coated with gold under vacuum and observed with a JEOL
6610LV scanning electron microscope, (JEOL co., Tokyo, Japan) at 20kV accelerated voltage.
Transplantation of HPCM in a rabbit model
DMEK surgery was performed in six New Zealand white rabbit. Rabbits were divided into
three groups: HPCM with or without cultured endothelial cells and rabbits with only peeled
off Descemet’s membrane.
Animals were anesthetized with buprenophine and meloxicam, and then intubated and
ventilated with isofluorane 2%. After topical administration of double anesthetic colicursi (tet-
racaine 0.1% and oxybuprocaine 0.4%), a 4mm wound incision was made at the limit of the
corneoescleral tissue of each right eye with a slit knife, and the corneal endothelium was
removed from the anterior chamber with a 30-gauge needle. HPCM with or without rabbit
CECs were cut using an 8.5mm diameter trephine and stained with trypan blue solution.
Grafts of HPCM, as a half-rolled taco, were placed in a disposable inserting set for Descemet
lenticle with a viscoelastic agent (E.Janach, Como, Italy), injected and unfolded into the
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anterior chamber and fixed to the posterior stroma stripped of Descemet´s membrane (Fig 1).
The sclerocorneal wound was closed with nylon sutures and a subconjunctival dose of Trigon
Depot (triamcinolone acetonide 40mg/ml) was administered.
After transplantation, rabbits were treated with Tobradex (dexamethasone 1mg/ml + tobra-
mycin 3mg/ml) and Timabak (timolol 2.5mg/ml) eye drops twice a day during all the follow-
up period. The exterior appearance of rabbit eyes was monitored by taking photographs at the
day of surgery, 24h after surgery, and once a week for the duration of the experiment. Six
weeks after transplantation, corneal thickness was measured by anterior segment optical
coherence tomography (AS-OCT) using a OCT CASIA SS-100 (Tomey, Erlangen, Germany).
Finally, rabbits were euthanized by an intravenous overdose of pentobarbital sodium.
Corneas were excised, rinsed with PBS solution and fixed using ice-cold methanol for 4h.
Corneal tissues were embedded in paraffin and then, hematoxylin-eosin (H-E) stain and
immunostaining against ZO-1 and Na+/K+ ATPase was performed as described in the previ-
ous section.
Results
Assessment of collagen content
The rate of type I collagen extraction was calculated from 10 independent isolations using dif-
ferent human cancellous bones. The mean soluble collagen contents were determined to be
0.23mg of collagen per mg of initial dry weight (Table 1). The mean concentration of the solu-
ble collagens was 2.46mg/ml. For each membrane, we used about 10mg collagen that allows
the preparation of at least 5 HPCM if employing the poorest collagen isolation.
Gel electrophoresis and western blot
The acid extract of human cancellous bone was subjected to SDS-8% acrylamide gel electro-
phoresis (Fig 2) and immunoblotting with polyclonal rabbit antibody to type I collagen (Milli-
pore, MA, USA). The SDS-PAGE band pattern of the purified material contained at least two
different α chains, but the separation of these two chains was not as pronounced as in the con-
trol group. Moreover, ß chain was also found in some of the samples as well as some low
molecular weight bands.
Collagen purity assessment
LC/MS analysis and posterior emPAI quantification are shown in Table 2. Type I collagen pro-
tein was present as a major product in all the purified samples (α1 = 64.35±1.86%mol;
Fig 1. DMEK surgical procedure for HPCM transplantation. (A) Descemetorrexis from the posterior stroma, (B) injected grafts of HPCM with
or without RCECs and (C) unfolded HPCM inside the anterior chamber.
doi:10.1371/journal.pone.0167578.g001
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α2 = 34.09±1.79%mol). Other collagenous proteins (type II, III, IV, V, XI and XII) were also
found as purification subproducts. Finally, residual contaminant proteins such as actin or type
I and type II keratins, were found in a 0.80±0.41%mol.
Preparation of the HPCM. HPCM were obtained by evaporating the soluble collagen
content of the purified extract and crosslinking by UV light exposure. Fabricated membranes
had an average area of 3.46cm2 and thickness of 20μm showing a randomly oriented fibrillar
structure when the surface was observed under SEM (Fig 3).
Table 1. Assessment of collagen content (mg) and collagen concentration (mg/ml).
Samples Dry weight (mg) Collagen isolation (ml) Collagen concentration (mg/ml) Total purified collagen (mg)
1 1,753 165 2.92 481.80
2 2,005 110 1.47 161.70
3 378 54 4.53 244.62
4 5,608 527 1.63 859.01
5 202 17 3.10 52.70
6 1,266 110 2.10 231.00
7 2,145 175 2.24 392.00
8 2,383 198 1.62 320.76
9 754 49 2.00 98.00
10 634 47.50 2.98 141.55
doi:10.1371/journal.pone.0167578.t001
Fig 2. Analysis by SDS-PAGE and immunobloting of type I collagen preparation from human cancellous
bone. Control group: lane 1; Samples: lanes 2, 3, 4 and 5.
doi:10.1371/journal.pone.0167578.g002
Artificial Tissue Engineered Endothelial Grafts Using Human Type I Collagen
PLOS ONE | DOI:10.1371/journal.pone.0167578 December 1, 2016 8 / 18
Optical analysis and mechanical testing
As shown in Fig 4, HPCM was optically transparent at all wavelengths of the visible light elec-
tromagnetic spectrum with a mean value of light transmission of 78.10±1.77% and 77.89
±1.43% in crosslinked and non-crosslinked HPCM respectively, showing no significant differ-
ences at any point of the visible light electromagnetic spectrum. When these values were com-
pared with the light transmission of a control human cornea (67.84±2.51), crosslinked and
non-crosslinked HPCM displayed statistically significantly higher values (p<0.01).
Mechanical testing revealed an enhancement in both: the resistance, determined by the
burst strength, and the elasticity, determined by the distance at burst in the crosslinked
HPCM. This difference (p<0.01) was statistically significant compared to the non-crosslinked
HPCM (Table 3).
Isolation, culture and examination of corneal endothelial cells on HPCM
Human CECs were observed to have migrated from the explant onto the plate after 3–4 days
in culture, and by day 30 a monolayer of compact cells had formed on the plate, immediately
adjacent to the explant in 13 of the 26 peripheral endothelial rings processed. These cell dis-
played their typical hexagonal endothelial morphology, while in the other 13 cultures, cells
showed signs of endothelial-mesenchymal transition resulting in the loss of corneal endothelial
specific hexagonal morphology and transformation into an elongated and fibroblast like
abnormal phenotype (Fig 5). No significant differences were found between different endothe-
lial cultures when comparing cell density, determined prior to the surgery, or age of the cor-
neal donors (Table 4). After 30 days, confluent hexagonal endothelial cells were detached and
subcultured on HPCM. In the same way, rabbit CECs were able to attach and proliferate when
isolated, by trypsin/EDTA digestion, and subcultured on HPCM.
Table 2. %mol of proteins determined by LC/MS.
Samples Type I collagen Other collagenous proteins Non-collagenous proteins
α1 α2 Type II Type III Type IV Type V Type XI Type XII
1 64.18 35.44 0.09 (α1) 0.09 (α1) 0.04 (α5) - - - 0.15
2 69.3 28.64 0.32 (α1) 0.61 (α1) - 0.06 (α1) 0.03 (α1) 0.03 (α2) - 0.95
3 58.73 37.21 0.39 (α1) 0.83 (α1) - - - 0.06 (α1) 2.78
4 68.18 30.56 0.19 (α1) 0.45 (α1) 0.03 (α5) 0.08 (α1) 0.08 (α2) 0.03 (α1) 0.03 (α2) - 0.39
5 66.62 32.35 0.08 (α1) 0.38 (α1) 0.04 (α5) 0.08 (α1) 0.04 (α1) - 0.36
6 59.10 40.32 0.14 (α1) 0.07 (α1) 0.01 (α5) 0.06 (α1) 0.05 (α2) 0.01 (α1) 0.01 (α2) - 0.19
doi:10.1371/journal.pone.0167578.t002
Fig 3. (A) Macrophotograph appearance of HPCM, (B) SEM microphotograph displaying fibrillary ultrastructure and (C) thickness of HPCM.
doi:10.1371/journal.pone.0167578.g003
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Under phase contrast microscope and SEM, human CECs and rabbit CECs demonstrated
their ability to attach and proliferate when cultured on HPCM, maintaining their polygonal
morphology (Fig 6).
Immunohistochemical analysis revealed a positive stain for ZO-1, a tight junction associ-
ated protein responsible for establishing the passive permeability properties of the endothelial
barrier and Na+/K+ ATPase, an integral membrane protein responsible for regulating pump
functions. Additionally, it also showed a positive stain for a newly formed basal membrane
protein, type IV collagen (Figs 7 and 8).
Transplantation of HPCM
Corneal edema and white turbidity appeared few days after surgery in the three groups, rabbits
transplanted with or without rabbit CECs cultured on HPCM and rabbits with only Desce-
met’s membrane peeled (Fig 9). Transplanted corneas with cultured rabbit CECs on HPCM
began to become transparent by day 10 and corneal transparency was maintained up to 6
weeks. However, the eyes in the group without rabbit CECs on HPCM and rabbits with peeled
off Descemet’s membrane did not restore corneal transparency and retained a corneal edema
during the follow up period. No obvious signs of immune rejection were found in any group.
Results of AS-OCT revealed HPCM with cultured endothelial cells as a fully integrated
component in the corneal tissue, displaying a similar corneal thickness when compared to its
healthy contralateral cornea. On the other hand, HPCM without corneal endothelial cells and
Fig 4. Optical properties (% light transmission) of crosslinked, non-crosskinked HPCM and human control cornea.
doi:10.1371/journal.pone.0167578.g004
Table 3. Mechanical properties of HPCM calculated using TA.TXplus texturometer (values are shown
as mean±SEM).
Crosslinked membranes Non-crosslinked membranes
Burst strength (g) 178.12±19.46 19.78±7.24
Distance at burst (mm) 2.53±0.27 0.78±0.33
doi:10.1371/journal.pone.0167578.t003
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rabbits with peeled off Descemet’s membrane only revealed an enhancement in corneal thick-
ness reflecting a loss of corneal endothelial functionality (Fig 10).
The histological analysis showed a slightly marked fibrotic tissue in the posterior segment
of the stroma in rabbits transplanted without corneal endothelial cells on HPCM and an
apparent corneal edema and fibrotic tissue in the rabbits with peeled off Descemet’s mem-
brane. HPCM, in rabbits transplanted with cultured cells, was attached tightly to the corneal
stroma and rabbit CECs formed a continuous monolayer with the same morphology and phe-
notypical markers, ZO-1 and Na+/K+ ATPase, as a healthy control eye (Fig 11). No sign of
endothelia remains were found in any of the transplanted corneas.
Hematoxilin-eosin stain (top row), ZO-1 (middle row) and Na+/K+ ATPase (bottom row)
immunofluorescence of: control healthy cornea (first column), transplanted HPCM with (sec-
ond column) or without (third column) rabbit CECs and cornea with only peeled off Desce-
met’s membrane (fourth column) at 6 weeks. Nuclei stained in blue.
Discussion
Human corneal endothelial cellular loss or damage leads to stromal edema, loss of transpar-
ency, and will eventually lead to blindness, requiring a healthy endothelial layer to reverse the
edema [44]. Nowadays the lack of corneal tissue is one of the hardest hurdles to overcome for
corneal repair. This barrier is even more pronounced in countries with a poor donation system
or in those whose ethics or religious convictions forbid tissue and organ donations.
Cell therapies and tissue engineering may be the future tools that allows these limitations to
be surpassed through the optimization of protocols for the in vitro expansion of human CECs
and the development of tissue-engineered scaffolds.
Fig 5. Microphotographs of human CEC displaying hexagonal and endothelial-mesenchymal transformed morphology.
doi:10.1371/journal.pone.0167578.g005
Table 4. Human CEC cultures displaying typical hexagonal cell morphology or endothelial-mesen-
chymal transformation grouped by endothelial cell density, determined prior to surgery, and age of
the corneal donors (values are shown as mean±SEM).
Age (years) Cellular density (cell/mm2)
Typical hexagonal cell morphology 64.33±2.69 2,546±121.8
Endothelial-mesenchymal transformation 61.91±3.57 2,760±107
doi:10.1371/journal.pone.0167578.t004
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In recent years, the culture technics of human CECs have been extensively improved allow-
ing their isolation and expansion in culture [45,46]. A large number of studies have demon-
strated the possibility of transplanting them in animal models with [25] or without [47] a
carrier. Intracameral injection of CECs for corneal endothelial dysfunctions has appeared as a
promising therapy, even more so if it is associated with the use of ROCK kinase inhibitor to
enhance the attachment of injected CECs [3,48]. However, these new approaches will have to
overcome the problems associated with injection of CECs, such as systemic dispersion of
CECs. At the moment, the use of a scaffold that allows the growth of CECs appears as a better
Fig 6. (A) SEM and (B) phase contrast microscopy micrographs of human CECs growing on HPCM.
doi:10.1371/journal.pone.0167578.g006
Fig 7. (A, B&C) Whole-mount and (D, E&F) frozen section immunostains of human CEC cultured on HPCM. ZO-1 (A&D), Na+/K+ ATPase
(B&E) and type IV collagen (C&F). Nuclei stained in blue.
doi:10.1371/journal.pone.0167578.g007
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way to control the corneal attachment of CECs. However, future studies will need to elucidate
the most effective treatment for corneal endothelial dysfunctions.
Fig 8. (A, B&C) Whole-mount and (D, E&F) frozen section immunostains of rabbit CEC cultured on HPCM. ZO-1 (A&D), Na+/K+ ATPase
(B&E) and type IV collagen (C&F). Nuclei stained in blue.
doi:10.1371/journal.pone.0167578.g008
Fig 9. Macrophotographs of the exterior appearance of transplanted rabbit eyes during the 6 week follow-up period.
doi:10.1371/journal.pone.0167578.g009
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Fig 10. AS-OCT of transplanted rabbit corneas displaying corneal thickness at 6 weeks.
doi:10.1371/journal.pone.0167578.g010
Fig 11. Histological analysis of transplanted rabbit corneas.
doi:10.1371/journal.pone.0167578.g011
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Different scaffolds have already been used as artificial Descemet’s membrane for the growth
of human CECs. Several groups have used bovine or porcine type I collagen as scaffold for
these purposes, showing in different animal models that corneal endothelial dysfunctions can
be treated [25,30].
However, the clinical application of tissue engineered therapies should avoid the use of
xenogeneic products as far as possible. For this purpose, we have developed an artificial endo-
thelial graft using type I collagen isolated from remnant human cancellous bone.
The analysis of emPAI based molar fractions of our samples demonstrate that type I colla-
gen can be isolated in a relatively easy, short and reproducible process (with a low presence of
different bone associated collagens and residual contaminants) from cancellous bones rou-
tinely processed in tissue banks. In our local tissue bank 8,000cc of cancellous bone are pro-
cessed every year and, in many donors, small tissue remnants (4-10cc) are left unused. These
cancellous bone remnants could potentially be used for type I collagen isolation.
Moreover, this product is safe because the donors are selected based on their clinical history
and serological tests (HIV; HVB; HCV and syphilis) and its origin is traceable because tissue
banks stores the donor´s data.
In the present study, and using the isolated collagen, we developed a HPCM with a thick-
ness similar to Descemet´s membrane. These HPCM needed to be crosslinked by UV light to
increase their mechanical properties (resistance and elasticity), however, light transmission
values weren’t affected and HPCM still showed better optical qualities than a normal human
cornea.
On the other hand, we cultured human CECs from peripheral endothelium of corneas pre-
viously used as grafts for PK; peripheral ring cells have more regenerative capacity [49] and are
a source of cells that are not used in transplant procedures. Per peripheral ring and with the
culture method here described, we are able to obtain a HPCM of 11mm in diameter cultured
with polygonal human CECs in one out of two corneas processed. This was not related to the
age nor the endothelial cellular density of corneal donors, suggesting, as previously described
[50], a direct relationship between the relative health of the donors before death as well as the
period between death, tissue processing and cellular culture in the ability of these cells to grow
and its outcome in culture. HPCM have proven to be a good substrate for human CECs since
cells growing on HPCM expressed characteristic markers, such as ZO-1 and Na+/K+ ATPase.
Moreover, they also expressed type IV collagen, a protein present in the Descemet’s mem-
brane, displaying the same expression pattern as that found in a healthy corneal endothelium.
To evaluate in vivo application of our artificial endothelial grafts, we performed a DMEK
surgery in a rabbit model. After surgery, no signs of immunological rejection were found, and
the HPCM with cultured rabbit CECs were able to restore corneal transparency in the trans-
planted corneas, appearing as a fully integrated lamellar graft in H-E stain with a normal cor-
neal thickness as shown by AS-OCT. Moreover, not finding any sign of endothelium remains
indicates that a complete descemetorrexis was performed. This implies that the restoration of
corneal transparency did not originate from autologous cell proliferation. Additionally, immu-
nofluorescence results indicate that rabbit CECs formed a continuous monolayer with the
same phenotypical markers that in a control cornea.
Nevertheless, our current work scheme still has some issues to resolve. We are currently
using a commercially available porcine derived pepsin in the extraction process, because this
protease produces a better yield of collagen extraction. Moreover, we use FBS for the culture of
human CECs. In future works, it is desirable that xenogeneic products were replace by human
derived products.
In conclusion, our work shows that it is possible to generate new artificial lamellar endothe-
lial grafts using human type I collagen and endothelial cells from remnant tissues from tissue
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banks and that these artificial lamellar endothelial grafts can be transplanted in a rabbit model
with satisfactory results. With this new approach it could be possible to increase the total num-
ber of patients grafted by generating new artificial endothelial lamellar grafts.
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